Form D · Biotechnology
VIVEVE MEDICAL, INC.
Englewood, CO · CIK 0000879682
Offering snapshot reported Oct 27, 2022 · SEC filing
- Reported sold
- $14.7K Offering amount: $14.7K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 14, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 27, 2022 | Initial | $14,675 | No comparison | 1 | SEC filing |
| Jun 18, 2020 | Initial | $341,250 | No comparison | 1 | SEC filing |
| May 4, 2020 | Initial | $3,225,875 | No comparison | 9 | SEC filing |
| Dec 3, 2015 | Initial | $6,001,369 | No comparison | 12 | SEC filing |
| May 27, 2015 | Initial | $12,000,000 | No comparison | 20 | SEC filing |
| Oct 8, 2014 | Initial | $2,411,081 | No comparison | 23 | SEC filing |
| Jun 10, 2014 | Initial | $500,000 | No comparison | 1 | SEC filing |
| Jun 4, 2014 | Initial | $6,000,000 | No comparison | 28 | SEC filing |
| Sep 27, 2013 | Initial | $1,750,000 | No comparison | 7 | SEC filing |
| Feb 25, 2013 | Initial | $4,040,000 | No comparison | 27 | SEC filing |
| Jan 17, 2013 | Initial | $250,000 | No comparison | 1 | SEC filing |
| Jul 9, 2012 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
| Mar 8, 2011 | Initial | $4,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-462946
Source: Form D, filed Oct 27, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| James Atkinson | Executive |
| Steven Basta | Director |
| Mark Colella | Director |
| Kevin J. Dunn | Director |
| Scott Durbin | Director, Executive |
| Benjamin L. Holmes | Director |
| Daniel Janney | Director |
| Debora Jorn | Director |
| Al Kyle | Director |
| Albert S. Kyle | Director |
| Kenneth J. Luppi | Executive |
| Gregory W. Mann | Director, Executive |
| Arlene Morris | Director |
| Brent Norton | Director |
| Edward H. Pendergast | Director |
| Sharon Presnell | Director |
| Vincent Puglisi | Executive |
| Jim Robbins | Executive |
| Robert I. Rudko | Director |
| Patricia Scheller | Director, Executive |
| Sean Shapiro | Executive |
| Carl Simpson | Director |
| Brigitte Smith | Director |
| Mark R. Tauscher | Director, Executive |
| James G. Thomasch | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
345 Inverness Drive South Building B, Suite 250
Englewood, CO, 80112
Englewood, CO, 80112